



**HIGHNOON**  
LABORATORIES LTD.

## Q2 REPORT 2015



growth  
by innovation

# Contents

---

Vision, Mission & Corporate Objectives	1
Company Information	2
Chairman's Review	3
Condensed Interim Financial Information	4
Independent Auditor's Review Report to the Members	6
Condensed Interim Balance Sheet	7
Condensed Interim Profit & Loss Account	9
Condensed Interim Statement of Comprehensive Income	10
Condensed Interim Cash Flow Statement	11
Condensed Interim Statement of Changes In Equity	13
Selected Notes to the Condensed Interim Financial Information	14

---

## Vision

We at Highnoon Laboratories Limited understand the duties of being responsible corporate citizen and stand true to our conviction and promise to work for the betterment and prosperity of our people.

“Highnoon for a Healthier Nation”

## Mission

We strive to maintain excellence in our business practices with the objective to benefit the medical community, consumers, stakeholders and employees; and to improve quality of life by providing quality products.

## Corporate Objectives

Excel in meeting customer needs.  
Maintain leadership in national pharmaceutical industry.  
Gain confidence of Doctors, Pharmacists and Consumers who use our products.  
Seek employee involvement, continuous improvement and enhanced performance goals.  
Enhance export business.

## Company Information

<b>Board of Directors</b>	Mr. Tausif Ahmad Khan Mr. Anees Ahmad Khan Dr. Adeel Abbas Mr. Ghulam Hussain Khan Mr. Taufiq Ahmed Khan Mr. Shazib Masud Mst. Siddiqa Begum Mrs. Zainub Abbas	Chairman Vice Chairman Chief Executive Officer
<b>Chief Financial Officer</b>	Mr. Javed Hussain Tel: +92(42)37511953 Email: javed@highnoon.com.pk	
<b>Company Secretary</b>	Mr. Khadim Hussain Mirza Tel: +92(42)37510036 Email: khadim@highnoon.com.pk	
<b>Bankers</b>	Habib Bank Limited United Bank Limited Faysal Bank Limited J.S. Bank Limited Allied Bank Limited Standard Chartered Bank (Pakistan) Limited	
<b>Registered, Head Office &amp; Plant</b>	17.5 Kilometer Multan Road, Lahore - 53700, Pakistan UAN: 111 000 465 Fax: +92 (42) 37510037 Email: info@highnoon.com.pk URL: www.highnoon-labs.com	
<b>Legal Advisors</b>	Raja Muhammad Akram & Company	
<b>Tax Advisors</b>	Yousuf Islam & Associates	
<b>Auditors</b>	Ernst & Young Ford Rhodes Sidat Hyder Chartered Accountants	
<b>Shares Registrar</b>	Corplink (Pvt) Ltd. Wings Arcade, 1-K Commercial, Model Town, Lahore. Tel: +92 (42) 35916714, 35916719, Fax: +92 (42) 35869637	

# CHAIRMAN'S REVIEW

On behalf of the Board of Directors, It is my pleasure to present the financial information for the half year that ended on 30th June 2015.

We maintained a strong momentum during the first half of 2015 and made progress towards achieving significant growth and higher productivity. Our growth remained driven by our core brands and our recently launched products supplemented our 18% top line growth. Our plant productivity improved significantly as we delivered over 30 million units during the period. Highnoon was able to keep pace with plant expansion and capacity enhancing projects due for completion by the end of 2015.

The Company successfully maintained its record double digit revenue growth as sales grew by 18% compared to corresponding period last year. Margins improved as a result of higher productivity, higher top line, better procurement and exchange rate stability.

Highnoon increased its profit after tax and earnings per share. Highnoon's right investments in marketing brought results even though distribution, selling and promotional expenses increased by 26%. This increase was due to the expansion of our sales team for increased penetration in the market. Administrative expenses were largely kept under control and increased in line with inflation and other staff related costs. Other operating expenses mainly represent statutory provisions that are dependent on profitability. As a result of growth in sales revenue and improved margins the Company was able to record 51 percent increase in profit after tax. Earnings per share remarkably increased to reflect Highnoon's correct investment strategy.

Highnoon continues to invest in new products and segments. I am pleased that the Board of Directors has approved an investment in Biocef (Pvt) Limited. The investee company envisages production of Cephalosporin range of antibiotics in a purpose built area. The investment is subject to the approval of shareholders in a general meeting.

On behalf of the Board, I would like to express my sincere gratitude to the Shareholders, Doctors, Pharmacist, Consumers, Business Partners and the Bankers for the continued patronage and to the employees and management for their continued, dedicated, untiring efforts and hard work.

For & On behalf of the Board

Lahore: 24 August 2015

Tausif Ahmad Khan  
Chairman



## CONDENSED INTERIM FINANCIAL INFORMATION

For the Half Year Ended  
30 June 2015

## INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS ON REVIEW OF INTERIM FINANCIAL INFORMATION

### Introduction


We have reviewed the accompanying condensed interim balance sheet of Highnoon Laboratories Limited as at 30 June 2015 and the related condensed interim profit and loss account, condensed interim statement of comprehensive income, condensed interim cash flow statement and condensed interim statement of changes in equity together with the notes forming part thereof, for the six-months period then ended (here-in-after referred to as the "interim financial information"). Management is responsible for the preparation and presentation of this interim financial information in accordance with approved accounting standards as applicable in Pakistan for interim financial reporting. Our responsibility is to express a conclusion on this interim financial information based on our review.

### Scope of Review

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim financial information is not prepared, in all material respects, in accordance with approved accounting standards as applicable in Pakistan for interim financial reporting.



Chartered Accountants

Engagement Partner: Farooq Hameed

Lahore: 24th August 2015

## CONDENSED INTERIM BALANCE SHEET

Un Audited      Audited  
30 June          31 December  
2015              2014

Note ----- (Rupees) -----

### EQUITY AND LIABILITIES

#### Share Capital And Reserves

##### Authorized Share Capital

25,000,000 (2014: 20,000,000)

	250,000,000	200,000,000
--	-------------	-------------

Share capital	203,621,790	181,805,170
---------------	-------------	-------------

Reserves	792,724,334	731,355,424
----------	-------------	-------------

	996,346,124	913,160,594
--	-------------	-------------

Surplus on revaluation of fixed assets	215,710,908	221,160,158
--	-------------	-------------

#### Non Current Liabilities

Liabilities against assets subject to finance lease

	42,638,904	30,273,913
--	------------	------------

Long term advances	13,936,041	13,056,828
--------------------	------------	------------

Deferred liabilities	265,456,018	269,169,709
----------------------	-------------	-------------

	322,030,963	312,500,450
--	-------------	-------------

#### Current Liabilities

Trade and other payables	458,962,672	409,027,390
--------------------------	-------------	-------------

Short term borrowings	1,146,431	-
-----------------------	-----------	---

Markup payable on secured loans	113,930	224,687
---------------------------------	---------	---------

Current portion of long term liabilities	41,784,464	33,282,639
--	------------	------------

Income Tax - Net	92,240,451	55,637,689
------------------	------------	------------

	594,247,948	498,172,405
--	-------------	-------------

<b>TOTAL EQUITY AND LIABILITIES</b>	<b>2,128,335,943</b>	<b>1,944,993,607</b>
-------------------------------------	----------------------	----------------------

#### CONTINGENCIES AND COMMITMENTS

5

The annexed notes from 1 to 12 form an integral part of this condensed interim financial information.



DR. ADEEL ABBAS  
CHIEF EXECUTIVE OFFICER

## AS AT 30 JUNE 2015

Un Audited      Audited  
30 June          31 December  
2015              2014

Note ----- (Rupees) -----

### ASSETS

#### Non Current Assets

Property, plant and equipment	6	776,222,838	759,544,053
-------------------------------	---	-------------	-------------

Intangible assets		55,244,386	63,510,996
-------------------	--	------------	------------

Long term deposits		1,562,054	1,562,054
--------------------	--	-----------	-----------

		833,029,278	824,617,103
--	--	-------------	-------------

#### Current Assets

Stock in trade	7	685,208,355	634,792,103
----------------	---	-------------	-------------

Trade debts		96,251,359	75,535,273
-------------	--	------------	------------

Advances		83,428,870	43,258,150
----------	--	------------	------------

Trade deposits and short term prepayments		26,338,868	17,637,699
---	--	------------	------------

Interest accrued		-	359,589
------------------	--	---	---------

Other receivables		1,819,566	1,485,660
-------------------	--	-----------	-----------

Balance with statutory authorities		4,458,857	11,983,557
------------------------------------	--	-----------	------------

Cash and bank balances		397,800,790	335,324,473
------------------------	--	-------------	-------------

		1,295,306,665	1,120,376,504
--	--	---------------	---------------

<b>TOTAL ASSETS</b>		<b>2,128,335,943</b>	<b>1,944,993,607</b>
---------------------	--	----------------------	----------------------



ANEES AHMAD KHAN  
DIRECTOR

**CONDENSED INTERIM  
PROFIT AND LOSS ACCOUNT (UN AUDITED)**  
For the Six Month Period Ended 30 June 2015

	Note	Six Month Ended 30 June		Three Month Ended 30 June	
		2015	2014	2015	2014
		----- (Rupees) -----		----- (Rupees) -----	
Sales - net	8	2,166,464,083	1,842,064,074	1,144,176,585	982,810,235
Cost of sales	9	(1,149,478,224)	(1,071,298,153)	(605,833,360)	(568,701,218)
<b>Gross profit</b>		<b>1,016,985,859</b>	<b>770,765,921</b>	<b>538,343,225</b>	<b>414,109,017</b>
<b>Operating expenses</b>					
Distribution, selling and promotional		(569,413,307)	(453,149,084)	(296,238,302)	(248,379,939)
Administrative and general		(125,183,629)	(103,633,485)	(64,896,044)	(54,638,961)
Research and development		(1,565,269)	(1,309,561)	(768,413)	(762,608)
Other operating charges		(31,190,183)	(20,416,770)	(17,765,191)	(10,819,500)
		(727,352,388)	(578,508,900)	(379,667,950)	(314,601,008)
		289,633,471	192,257,021	158,675,275	99,508,009
Other income		23,274,368	6,852,463	17,912,861	4,723,880
<b>Operating profit</b>		<b>312,907,839</b>	<b>199,109,484</b>	<b>176,588,136</b>	<b>104,231,889</b>
Finance cost		(5,441,888)	(8,843,468)	(3,008,879)	(5,000,918)
<b>Profit before taxation</b>		<b>307,465,951</b>	<b>190,266,016</b>	<b>173,579,257</b>	<b>99,230,971</b>
Taxation		(111,556,310)	(60,563,000)	(68,382,968)	(30,363,000)
<b>Profit after taxation</b>		<b>195,909,641</b>	<b>129,703,016</b>	<b>105,196,289</b>	<b>68,867,971</b>
			Restated		Restated
<b>Earnings per share-basic and diluted</b>		<b>9.62</b>	<b>6.37</b>	<b>5.17</b>	<b>3.38</b>

The annexed notes from 1 to 12 form an integral part of this interim financial information.



DR. ADEEL ABBAS  
CHIEF EXECUTIVE OFFICER



ANEES AHMAD KHAN  
DIRECTOR



DR. ADEEL ABBAS  
CHIEF EXECUTIVE OFFICER



ANEES AHMAD KHAN  
DIRECTOR

**CONDENSED INTERIM STATEMENT OF  
COMPREHENSIVE INCOME (UN AUDITED)**  
For the Six Month Period Ended 30 June 2015

	Six Month Ended 30 June	
	2015	2014
	----- (Rupees) -----	
Profit after tax for the period	195,909,641	129,703,016
Other comprehensive income	-	-
<b>Total comprehensive income for the period</b>	<b>195,909,641</b>	<b>129,703,016</b>

Surplus arising on 'revaluation of fixed assets' is presented under a separate head below equity as 'surplus on revaluation of assets' in accordance with the requirements specified by the Securities and Exchange Commission of Pakistan (SECP) vide its S.R.O.45(I)/2003 dated 13 January 2003 and section 235 of Companies Ordinance, 1984 respectively.

The annexed notes from 1 to 12 form an integral part of this condensed interim financial information.

**CONDENSED INTERIM  
CASH FLOW STATEMENT (UN AUDITED)  
For the Six Month Period Ended 30 June 2015**

	Six Month Ended 30 June	
	2015	2014
	----- (Rupees) -----	
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Profit before taxation	307,465,951	190,266,016
Adjustments for non-cash and other items:		
Depreciation	38,965,619	37,650,388
Amortization of intangible assets	9,111,966	9,024,633
Gain on disposal of property, plant and equipment	(4,982,882)	(4,406,589)
Exchange loss	5,056,584	4,622,302
Provision for defined benefit obligation	20,409,492	21,003,888
Finance cost	5,441,888	8,843,468
	74,002,667	76,738,090
<b>Profit before working capital changes</b>	<b>381,468,618</b>	<b>267,004,106</b>
<b>Working Capital Changes</b>		
<i>(Increase)/decrease in current assets:</i>		
Stock in trade	(50,416,252)	(89,714,785)
Trade debts	(20,716,086)	(15,925,423)
Advances	(40,170,720)	(4,890,490)
Trade deposits and short term prepayments	(8,701,169)	-
Interest accrued	359,589	-
Other receivables	(333,906)	213,441
Balances with statutory authorities	7,524,700	6,583,342
<i>Increase/(decrease) in current liabilities:</i>		
Trade and other payables	41,084,405	55,019,083
	(71,369,439)	(48,714,832)
<b>Cash generated from operations</b>	<b>310,099,179</b>	<b>218,289,274</b>
Taxes paid	(72,152,055)	(41,820,290)
Gratuity paid	(26,924,676)	(7,719,966)
Finance cost paid	(1,835,001)	(6,082,336)
Long term advances - net	1,659,959	651,612
<b>Net cash generated from operating activities</b>	<b>210,847,406</b>	<b>163,318,294</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Capital expenditure incurred	(37,335,776)	(6,839,689)
Intangible assets acquired	(845,356)	(504,650)
Proceeds from disposal of property, plant and equipment	17,252,754	8,152,596
<b>Net cash flow (used in)/from investing activities</b>	<b>(20,928,378)</b>	<b>808,257</b>

	Six Month Ended 30 June	
	2015	2014
	----- (Rupees) -----	
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Repayment of finance lease liabilities	(14,210,074)	(26,255,025)
Long term financing repayment	-	(50,000,000)
Short term borrowings- net	1,146,431	157,632
Dividend paid	(114,379,068)	(71,805,454)
<b>Net cash flow used in financing activities</b>	<b>(127,442,711)</b>	<b>(147,902,847)</b>
<b>Net increase in cash and cash equivalents</b>	<b>62,476,317</b>	<b>16,223,704</b>
Cash and cash equivalents at beginning of the period	335,324,473	49,533,292
<b>Cash and cash equivalents at end of the period</b>	<b>397,800,790</b>	<b>65,756,996</b>

The annexed notes from 1 to 12 form an integral part of this condensed interim financial information.



DR. ADEEL ABBAS  
CHIEF EXECUTIVE OFFICER




ANEES AHMAD KHAN  
DIRECTOR



**CONDENSED INTERIM STATEMENT  
OF CHANGES IN EQUITY (UN AUDITED)**  
For the Six Month Period Ended 30 June 2015

	Share Capital	Revenue Reserves			Total
		General Reserves	Unappropriated Profit	Sub Total	
----- Rupees -----					
Balance as at 01 January 2014	181,805,170	114,000,000	419,568,145	533,568,145	715,373,315
Profit for the period ended 30 June 2014	-	-	129,703,016	129,703,016	129,703,016
Other comprehensive income	-	-	-	-	-
Total comprehensive income for the period	-	-	129,703,016	129,703,016	129,703,016
Final dividend @ Rs. 4.50 per share for the year ended 31 December 2013	-	-	(81,812,327)	(81,812,327)	(81,812,327)
Incremental depreciation relating to surplus on revaluation of fixed assets	-	-	4,307,687	4,307,687	4,307,687
Balance as at 30 June 2014	<u>181,805,170</u>	<u>114,000,000</u>	<u>471,766,521</u>	<u>585,766,521</u>	<u>767,571,691</u>
<b>Balance as at 01 January 2015</b>	<b>181,805,170</b>	<b>114,000,000</b>	<b>617,355,424</b>	<b>731,355,424</b>	<b>913,160,594</b>
Profit for the period ended 30 June 2015	-	-	195,909,641	195,909,641	195,909,641
Other comprehensive income	-	-	-	-	-
Total comprehensive income for the period	-	-	195,909,641	195,909,641	195,909,641
Issuance of bonus shares @ 12%	21,816,620	-	(21,816,620)	(21,816,620)	-
Final dividend @ Rs. 6.50 per share for the year ended 31 December 2014	-	-	(118,173,361)	(118,173,361)	(118,173,361)
Incremental depreciation relating to surplus on revaluation of fixed assets	-	-	5,449,250	5,449,250	5,449,250
Balance as at 30 June 2015	<u>203,621,790</u>	<u>114,000,000</u>	<u>678,724,334</u>	<u>792,724,334</u>	<u>996,346,124</u>

The annexed notes from 1 to 12 form an integral part of this condensed interim financial information.

  
DR. ADEEL ABBAS  
CHIEF EXECUTIVE OFFICER

  
ANEES AHMAD KHAN  
DIRECTOR

**SELECTED NOTES TO THE CONDENSED  
INTERIM  
FINANCIAL INFORMATION (UN AUDITED)**  
For the Six Month Period Ended 30 June 2015

**1. THE COMPANY AND ITS OPERATIONS**

Highnoon Laboratories Limited ('the Company') was incorporated as a private limited company in Pakistan in 1984 and converted into an unquoted public limited company in 1985. Its shares are quoted on all three stock exchanges in Pakistan since November 1994. The Company is principally engaged in the manufacture, import, sale and marketing of pharmaceutical and allied consumer products. The registered office of the Company is situated at 17.5 Km, Multan Road, Lahore.

**2. STATEMENT OF COMPLIANCE**

- 2.1 This condensed interim financial information of the Company for the six months ended 30 June 2015 has been prepared in accordance with the requirements of the International Accounting Standard 34 - Interim Financial Reporting and provisions of and directives issued under the Companies Ordinance, 1984. In case where requirements differ, the provisions of or directives issued under the Companies Ordinance, 1984 have been followed.
- 2.2 This condensed interim financial information is un-audited and is being submitted to shareholders, as required by section 245 of the Companies Ordinance, 1984.

**3. BASIS OF PREPARATION**

- 3.1 This condensed interim financial information does not include all the information and disclosures required in annual financial statements, and should be read in conjunction with the Company's annual financial statements as at 31 December 2014.
- 3.2 The accounting policies adopted for the preparation of this condensed interim financial information are the same as those applied in the preparation of the preceding annual published financial statements of the Company for the year ended 31 December 2014 except for as disclosed in note 3.3 below.
- 3.3 The Company has adopted the following revised standard, amendments and interpretation of IFRSs which became effective for the current period:

IFRS 10 – Consolidated Financial Statements

IFRS 10 – Consolidated Financial Statements, IFRS 12 Disclosure of Interests in Other Entities and IAS 27 Separate Financial Statements – Investment Entities (Amendment)

IFRS 11 – Joint Arrangements

IFRS 12 – Disclosure of Interests in Other Entities

IFRS 13 – Fair Value Measurement

IAS 19 – Employee Benefits - (Amendment) - Defined Benefit plans: Employee Contributions.

The adoption of the above amendment to accounting standards did not have any effect on the condensed interim financial statements.

**4. ACCOUNTING ESTIMATES AND JUDGMENTS**

The preparation of condensed interim financial information requires management to make judgments, estimates and assumptions that affect the application of accounting policies and reported amount of assets and liabilities, incomes and expenses. Actual results may differ from these estimates. The significant judgments made by management in applying the Company's accounting policies and the key sources of estimation are the same as those that applied to the financial statements for the year ended 31 December 2014.

## 5. CONTINGENCIES AND COMMITMENTS

### Contingencies:

There is no significant change in the contingencies since the date of preceding published annual financial statements.

### Commitments:

Commitments against irrevocable letters of credit include:

	Un Audited 30 June 2015	Audited 31 December 2014
Note	----- (Rupees) -----	
Raw materials	163,115,736	169,018,435
Packing materials	59,160,749	16,624,255
Finished goods	19,475,550	14,984,750
Plant and machinery	40,164,464	39,726,075
	<u>281,916,499</u>	<u>240,353,515</u>

## 6. PROPERTY, PLANT AND EQUIPMENT

Operating fixed assets - (owned)	(6.1)	658,831,504	669,818,556
Operating fixed assets - (leased)	(6.2)	98,178,599	81,423,968
Capital work-in-progress	(6.3)	19,212,735	8,301,529
		<u>776,222,838</u>	<u>759,544,053</u>

### 6.1 Operating fixed assets (owned)

Opening book value		669,818,556	694,898,950
Add: Additions during the period / year - cost	(6.1.1)	26,424,570	39,442,119
Transferred during the period / year -vehicles		5,184,768	7,625,855
		31,609,338	47,067,974
Less: Deletions during the period / year	(6.1.2)	12,269,872	7,932,174
Depreciation during the period / year		30,326,518	64,216,194
		42,596,390	72,148,368
Book value at the end of the period / year		<u>658,831,504</u>	<u>669,818,556</u>

#### 6.1.1 Additions during the period / year - cost

Building on freehold land	2,282,599	-
Plant and machinery	2,384,050	2,975,340
Laboratory equipment	1,357,400	8,814,112
Furniture and fixtures	494,901	155,928
Electric and gas appliances	1,650,249	1,162,400
Office equipment	1,437,732	1,971,739
Vehicles	16,817,639	24,362,600
	<u>26,424,570</u>	<u>39,442,119</u>

### 6.1.2 Deletions during the period / year

	Un Audited 30 June 2015	Audited 31 December 2014
	----- (Rupees) -----	
Plant and machinery	2,172,389	-
Office equipment	222,056	367,501
Vehicles	9,875,427	7,564,673
	<u>12,269,872</u>	<u>7,932,174</u>

### 6.2 Operating fixed assets (leased)

Opening book value	81,423,968	52,614,628
Add: Additions during the period / year - cost	30,578,500	50,944,000
	112,002,468	103,558,628
Less: Transfers during the period / year	5,184,768	7,625,855
Depreciation during the period / year	8,639,101	14,508,805
	13,823,869	22,134,660
Book value at the end of the period / year	<u>98,178,599</u>	<u>81,423,968</u>

### 6.3 Capital work in progress

Civil works	207,134	1,763,058
Plant and machinery - owned	2,787,101	2,967,471
Advance to suppliers (for purchase of vehicles)	16,218,500	3,571,000
	<u>19,212,735</u>	<u>8,301,529</u>

## 7. STOCK IN TRADE

Raw materials		
In hand	358,838,969	298,815,977
In transit	12,157,858	10,094,743
	370,996,827	308,910,720
Packing materials		
In hand	118,350,876	120,532,834
In transit	12,109,590	-
	130,460,466	120,532,834
Work in process	60,851,491	55,356,113
Finished goods		
In hand	121,252,379	149,221,552
With third party	1,647,192	770,884
	122,899,571	149,992,436
	<u>685,208,355</u>	<u>634,792,103</u>

	Un-Audited			
	Six Month Ended		Three Month Ended	
	30 June		30 June	
	2015	2014	2015	2014
----- Rupees -----				
<b>8. SALES - net</b>				
Manufactured products				
Local	1,923,745,466	1,692,017,646	1,013,202,382	913,796,863
Export	149,123,197	124,887,373	79,144,328	59,123,061
	2,072,868,663	1,816,905,019	1,092,346,710	972,919,924
Purchased products-Local	36,081,306	17,059,131	12,549,676	13,472,315
Third Party	221,347,263	164,868,283	124,798,795	80,181,914
	2,330,297,232	1,998,832,433	1,229,695,181	1,066,574,153
Less: Discount	156,801,929	151,039,624	82,210,591	79,016,685
Sales tax	7,031,220	5,728,735	3,308,005	4,747,233
	163,833,149	156,768,359	85,518,596	83,763,918
	<u>2,166,464,083</u>	<u>1,842,064,074</u>	<u>1,144,176,585</u>	<u>982,810,235</u>

## 9. COST OF SALES

Opening stock of finished goods (excluding purchased products)	140,089,826	102,090,848	165,910,969	94,492,920
Cost of goods manufactured	1,099,820,855	1,036,839,565	543,495,803	545,294,596
	1,239,910,681	1,138,930,413	709,406,772	639,787,516
Closing stock of finished goods	(109,880,781)	(79,047,644)	(109,880,781)	(79,047,644)
Cost of sales - Manufactured	1,130,029,900	1,059,882,769	599,525,991	560,739,872
Cost of sales - Purchased products	19,448,324	11,415,384	6,307,369	7,961,346
	<u>1,149,478,224</u>	<u>1,071,298,153</u>	<u>605,833,360</u>	<u>568,701,218</u>

## 10. RELATED PARTY TRANSACTIONS

The related parties comprises associated companies, staff retirement funds, directors and key management personnel. Transactions with related parties are as stated below:

	Un-Audited			
	Six Month Ended		Three Month Ended	
	30 June		30 June	
	2015	2014	2015	2014
----- Rupees -----				
<b>10.1 Sales of goods</b>				
Associated Company	16,876,729	43,631,565	5,058,176	21,207,945
<b>10.2 Contribution towards employees' benefits</b>				
Staff provident fund	9,117,469	7,598,681	4,643,172	3,833,417
Employees' welfare trust	774,750	632,195	400,200	324,945

	Un-Audited			
	Six Month Ended		Three Month Ended	
	30 June		30 June	
	2015	2014	2015	2014
----- Rupees -----				
<b>10.3 Remuneration</b>				
CEO	4,515,782	6,330,717	2,039,877	3,634,917
Directors	12,874,345	13,804,409	13,489,542	7,277,577
Executives	89,121,340	95,618,606	33,251,169	48,029,046
			<u>Un-Audited</u>	<u>Audited</u>
			<u>30 June</u>	<u>31 December</u>
			<u>2015</u>	<u>2014</u>
			----- (Rupees) -----	

## 10.4 The outstanding balances of related parties are as under:


Relationship with the Company	Nature of balance		
Associated company	Creditors	<u>515,232</u>	<u>251,200</u>
Staff provident fund	Contribution payable	<u>3,147,197</u>	<u>2,530,613</u>
Employees' welfare trust	Contribution payable	<u>339,435</u>	<u>291,281</u>

## 11. DATE OF AUTHORIZATION FOR ISSUANCE

The Board of Directors of the Company authorized this condensed interim financial information for issuance on 24 August 2015.

## 12. GENERAL

- 12.1 The figures of condensed interim profit and loss account for the quarters ended 30 June 2015 and 2014 were not subject to limited scope review by the auditors as scope of review covered only the cumulative figures.
- 12.2 Provisions in respect of Worker's Welfare Fund, Worker's Profit Participation Fund, defined benefit plan and Taxation are estimated and these are subject to final adjustment in the annual audited financial statements.
- 12.3 Figures have been rounded off to the nearest rupee unless otherwise specified.

  
DR. ADEEL ABBAS  
CHIEF EXECUTIVE OFFICER

  
ANEES AHMAD KHAN  
DIRECTOR

BOOK  
POST

[www.highnoon-labs.com](http://www.highnoon-labs.com)



**HIGHNOON LABORATORIES LTD.**

17.5 Kilometer Multan Road,  
Lahore - 53700, Pakistan.

Phone: +92 (42) 111 000 465

Fax: +92 (42) 3751 0037

Email: [info@highnoon.com.pk](mailto:info@highnoon.com.pk)

